Literature DB >> 23052159

Daily on-line set-up correction in 3D-conformal radiotherapy: is it feasible?

Francesco Deodato1, Savino Cilla, Mariangela Massaccesi, Gabriella Macchia, Edy Ippolito, Luciana Caravatta, Vincenzo Picardi, Michele Romanella, Carlo Di Falco, Alessandra Bartollino, Vincenzo Valentini, Numa Cellini, Marco De Spirito, Angelo Piermattei, Alessio G Morganti.   

Abstract

AIMS AND
BACKGROUND: The aim of this report was to investigate the feasibility in terms of treatment time prolongation of an on-line no-action level correction protocol, based on daily electronic portal image verification. METHODS AND STUDY
DESIGN: The occupation of a linear accelerator (LINAC) delivering 3-D conformal treatments was monitored for two weeks (from Monday to Friday, 10 working days). An electronic portal image device I-View (Elekta, UK) was used for setup verification. Single-exposure portal images were acquired daily using the initial 8 monitor units delivered for each treatment field. Translational deviations of isocenter position larger than 5 mm or 7 mm, for radical or palliative treatments, respectively, were immediately corrected. In order to estimate the extra workload involved with the on-line protocol, the time required for isocenter check and table correction was specifically monitored.
RESULTS: Forty-eight patients were treated. In all, 482 fractions had electronic portal images taken. Two hundred and forty-five setup corrections were made (50.8% of all fractions). The occupation of the LINAC lasted 106 h on the whole. Twelve h and 25 min (11.7% of LINAC occupation time) were spent for portal image verification and setup correction. On the average, 4.3 fractions per hour were carried out.
CONCLUSIONS: When used by trained therapists, ideally, portal imaging may be carried out before each fraction, requiring approximately 10% of LINAC occupation time.

Entities:  

Mesh:

Year:  2012        PMID: 23052159     DOI: 10.1177/030089161209800407

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  10 in total

1.  On the cutting edge of intensity modulated radiotherapy and simultaneous integrated boost (IMRT-SIB): The case of a patient with 8 brain metastases.

Authors:  Marica Ferro; Savino Cilla; Gabriella Macchia; Francesco Deodato; Antonio Pierro; Cinzia Digesu'; Gabriella Ferrandina; Matteo Ciuffreda; Giuseppina Sallustio; Alessio G Morganti
Journal:  Rep Pract Oncol Radiother       Date:  2014-09-23

2.  Radiological and clinical results following high-dose intensity-modulated radiotherapy in recurrent craniopharyngioma: A case report.

Authors:  Antonio Pierro; Savino Cilla; Vincenzo Picardi; Marica Ferro; Gabriella Macchia; Francesco Deodato; Milly Buwenge; Giuseppina Sallustio; Alessio G Morganti
Journal:  Oncol Lett       Date:  2015-07-20       Impact factor: 2.967

3.  Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer.

Authors:  Mariangela Massaccesi; Edy Ippolito; Francesco Deodato; Savino Cilla; Cinzia Digesù; Gabriella Macchia; Luciana Caravatta; Vincenzo Picardi; Gian Carlo Mattiucci; Alessandra Di Lallo; Daniele Cuscunà; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Radiol Med       Date:  2013-12-06       Impact factor: 3.469

4.  Short-course regimen of palliative radiotherapy in complicated bone metastases: a phase i-ii study (SHARON Project).

Authors:  Jenny Capuccini; Gabriella Macchia; Eleonora Farina; Milly Buwenge; Domenico Genovesi; Luciana Caravatta; Nam P Nguyen; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Vincenzo Valentini; Francesco Deodato; Alessio G Morganti
Journal:  Clin Exp Metastasis       Date:  2018-08-18       Impact factor: 5.150

5.  Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial.

Authors:  Alessandra Guido; Dajana Cuicchi; Lorenzo Fuccio; Alessio G Morganti; Paolo Castellucci; Francesco Cellini; Francesca Di Fabio; Fabiola Lorena Rojas Llimpe; Lidia Strigari; Milly Buwenge; Savino Cilla; Francesco Deodato; Gabriella Macchia; Erika Galietta; Rita Golfieri; Andrea Ardizzoni; Rocco Maurizio Zagari; Stefano Fanti; Gilberto Poggioli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-21       Impact factor: 10.057

6.  Intensity-Modulated Radiotherapy with Concomitant Boost After Breast Conserving Surgery: A Phase I-II Trial.

Authors:  Francesco Deodato; Alessio G Morganti; Gabriella Macchia; Savino Cilla; Milly Buwenge; Alice Zamagni; Ilario Ammendolia; Claudio Zamagni; Giovanni P Frezza; Vincenzo Valentini
Journal:  Breast Cancer (Dove Med Press)       Date:  2020-11-12

7.  Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer: a dose-escalation study.

Authors:  Gabriella Macchia; Savino Cilla; Francesco Deodato; Francesco Legge; Aida Di Stefano; Vito Chiantera; Giovanni Scambia; Vincenzo Valentini; Alessio G Morganti; Gabriella Ferrandina
Journal:  Br J Radiol       Date:  2015-09-21       Impact factor: 3.039

8.  Efficacy and safety of 3D-conformal half body irradiation in patients with multiple bone metastases.

Authors:  Gabriella Macchia; Milena Ferro; Savino Cilla; Milly Buwenge; Anna Ianiro; Mariangela Boccardi; Vincenzo Picardi; Marica Ferro; Eleonora Arena; Alice Zamagni; Silvia Cammelli; Vincenzo Valentini; Alessio G Morganti; Francesco Deodato
Journal:  Clin Exp Metastasis       Date:  2018-09-24       Impact factor: 5.150

9.  Radiotherapy in palliation of thoracic tumors: a phase I-II study (SHARON project).

Authors:  Eleonora Farina; Gabriella Macchia; Milly Buwenge; Giambattista Siepe; Alice Zamagni; Silvia Cammelli; Savino Cilla; Tigeneh Wondemagegnhu; Aynalem A Woldemariam; A F M Kamal Uddin; Mostafà Aziz Sumon; Francesco Cellini; Francesco Deodato; Alessio G Morganti
Journal:  Clin Exp Metastasis       Date:  2018-10-08       Impact factor: 5.150

10.  Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors.

Authors:  Milly Buwenge; Erica Scirocco; Francesco Deodato; Gabriella Macchia; Maria Ntreta; Silvia Bisello; Giambattista Siepe; Savino Cilla; Anna Rita Alitto; Vincenzo Valentini; Lidia Strigari; Alessio G Morganti; Silvia Cammelli
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.